Molecular Targets Program, Department of Medicine, James Graham Brown Cancer Center, University of Louisville Louisville, KY, USA.
Front Oncol. 2011 Dec 28;1:54. doi: 10.3389/fonc.2011.00054. eCollection 2011.
RASSF1A is one of the most frequently inactivated tumor suppressors yet identified in human cancer. It is pro-apoptotic and appears to function as a scaffolding protein that interacts with a variety of other tumor suppressors to modulate their function. It can also complex with the Ras oncoprotein and may serve to integrate pro-growth and pro-death signaling pathways. A SNP has been identified that is present in approximately 29% of European populations [rs2073498, A(133)S]. Several studies have now presented evidence that this SNP is associated with an enhanced risk of developing breast cancer. We have used a proteomics based approach to identify multiple differences in the pattern of protein/protein interactions mediated by the wild type compared to the SNP variant protein. We have also identified a significant difference in biological activity between wild type and SNP variant protein. However, we have found only a very modest association of the SNP with breast cancer predisposition.
RASSF1A 是人类癌症中最常失活的肿瘤抑制因子之一。它具有促凋亡作用,似乎作为一种支架蛋白发挥作用,与多种其他肿瘤抑制因子相互作用,调节其功能。它还可以与 Ras 癌蛋白复合物,并可能用于整合促生长和促死亡信号通路。已经确定了一个 SNP,它存在于大约 29%的欧洲人群中[rs2073498,A(133)S]。现在有几项研究已经提供了证据,表明该 SNP 与乳腺癌发病风险增加有关。我们使用基于蛋白质组学的方法来鉴定与野生型相比,SNP 变异蛋白介导的蛋白质/蛋白质相互作用模式的多种差异。我们还发现野生型和 SNP 变异蛋白之间的生物学活性存在显著差异。然而,我们只发现 SNP 与乳腺癌易感性的相关性非常小。